CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney transplant patients facing advanced skin cancer
Disease control OngoingThis early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for tough merkel cell cancer: drug combo targets DNA repair
Disease control OngoingThis study tests whether adding a drug called tuvusertib (which blocks a DNA repair enzyme) to the immunotherapy avelumab can slow down advanced Merkel cell cancer that has stopped responding to standard immunotherapy. About 50 adults with this rare skin cancer will be randomly a…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC